Resolution Pharmaceuticals Inc.

Anne Goodbody

Alfred Pollak

John Thornback

Susan H Peers

Peptide derived radionuclide chelators

Peptide-chelator conjugates are provided that when labelled with a traceable metal are useful for diagnostic imaging of sites of inflammation. The peptide component is an antagonist of the naturally occurring tetrapeptide tuftsin while the chelator component serves as a labelling site for metals, in particular radionuclide metals such as technetium-99 m.

Peptide-chelator conjugates

Detectably labelled non-receptor mediated cell-associating compounds are provided for use in the diagnostic imaging of target sites in a mammal. Cell-associating compounds may be directly labelled, or labelled via a chelating compound to form a conjugate. Such cell-associating compounds are particularly useful to image target sites such as tumour sites and sites of infection.

Non-receptor cell mediated imaging agents

For use in imaging sites of diagnostic interest within the body, the present invention provides radionuclide chelators, optionally coupled to targeting molecules such as peptides of the formula: ##STR1##

Non-receptor mediated imaging agents

Peptide-chelator conjugates are provided that when labelled with a traceable metal are useful for diagnostic imaging of sites of inflammation. The peptide component is an antagonist of the naturally occurring tetrapeptide tuftsin while the chelator component serves as a labelling site for metals, in particular radionuclide metals such as technetium-99m.

Peptide-Chelator conjugates

Radionuclide chelating compounds are provided for conjugation to targetting molecules such as proteins, peptides or antibodies. The resulting labelled targetting molecules may be used in diagnosis and therapy.

Growing community of inventors

Toronto, Canada

Anne Goodbody